Skip to content
646 269 0773|alita@globalbioethics.org
facebooktwitterlinkedin
Global Bioethics Initiative (GBI) Logo Global Bioethics Initiative (GBI) Logo Global Bioethics Initiative (GBI) Logo
  • Home
  • About
  • Staff
    • Founders
    • Board of Directors
    • Advisory Board
    • Visiting Scholars
    • Student Interns
    • Volunteers
  • Events
  • Resources
    • COVID-19
  • Internships
  • Contact
  • Donate
Previous Next
  • View Larger Image stethoscope and money

The Health Care Costs Debate Gets Another Chance

GlaxoSmithKline’s new therapy sparks up the health care costs debate

With Biotech giant GlaxoSmithKline newly developed cure for “bubble-boy” disease, the health care costs debate gets another chance to take the public arena. The highly priced drug, Strimvelis, is a gene therapy for severe immune deficiency, giving children a chance to live well after the age of 2 with just a single dose.

Damian Garde argues that, even if current techniques take as much as $4 million dollars in over a decade and this new therapy would only require a single disbursement of $665,000, these giants will need to convince parents to give that amount in such a short period of time: in a one-time payment.

This brings insurers into the equation, who resist to those expenditures, specially when a purported cure wears off over time; and with the Affordable Care Act in place, copayments could mean no health care access at all. Which begs the everlasting question of the use of genetic technologies and their affordability for health care patients: will they ever be readily available to all?

You can read the whole article here.

Other Posts

Around 30%’ of eligible NY medical workers refusing COVID-19 vaccine: officialMalvika2021-01-10T13:28:50+00:00
Study suggests Pfizer vaccine works against virus variantMalvika2021-01-10T13:19:53+00:00
Rich Countries Have ‘Bought Up’ COVID-19 Vaccine Supply, Art Caplan SaysMalvika2020-12-18T13:39:02+00:00
First shipments of Pfizer vaccine to be delivered December 15Malvika2020-12-03T16:15:19+00:00
By Admin@gbi|2020-04-09T23:45:54+00:00August 4th, 2016|News-Articles|1 Comment

Share This Story, Choose Your Platform!

facebooktwitterlinkedinreddittumblrpinterestvkEmail

About the Author: Admin@gbi

Avatar

Related Posts

  • Around 30%’ of eligible NY medical workers refusing COVID-19 vaccine: official
    Around 30%’ of eligible NY medical workers refusing COVID-19 vaccine: official
    Gallery

    Around 30%’ of eligible NY medical workers refusing COVID-19 vaccine: official

  • Study suggests Pfizer vaccine works against virus variant
    Study suggests Pfizer vaccine works against virus variant
    Gallery

    Study suggests Pfizer vaccine works against virus variant

  • Rich Countries Have ‘Bought Up’ COVID-19 Vaccine Supply, Art Caplan Says
    Rich Countries Have ‘Bought Up’ COVID-19 Vaccine Supply, Art Caplan Says
    Gallery

    Rich Countries Have ‘Bought Up’ COVID-19 Vaccine Supply, Art Caplan Says

  • First shipments of Pfizer vaccine to be delivered December 15
    First shipments of Pfizer vaccine to be delivered December 15
    Gallery

    First shipments of Pfizer vaccine to be delivered December 15

  • Bioethicists worry the rich and powerful will get special access to experimental Covid treatments
    Bioethicists worry the rich and powerful will get special access to experimental Covid treatments
    Gallery

    Bioethicists worry the rich and powerful will get special access to experimental Covid treatments

One Comment

  1. Avatar
    Vikas Ravindra August 4, 2016 at 7:23 pm - Reply

    It’s Cost effective to humanity when it’s funding in Huge amount to research arena be capable to find focused solution rather than think about at anyhow for it’s became consistently it’s existence.

Leave A Comment Cancel reply

Recent Tweets

Tweets by GBISummerSchool

Find us on Facebook

Copyright 2012 - 2020 Global Bioethics | All Rights Reserved | Powered by Global Innovation Consortium
facebooktwitterlinkedin
Toggle Sliding Bar Area